biostudies-literatureUnknown51Ascaso-Del-Rio A<h4>Background</h4>There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens.<h4>Methods</h4>This multicentre, prospective controlled cohort study included subjects who received a COVID-19 experimental vaccine (CVnCoV)(test group, TG) - and unvaccinated subjects (control group, CG), selected among individuals to be vaccinated according to the Spanish vaccination program. All study subjects received BNT162b2 as a standard national vaccination schedule, except 8 (from CG) who received mRNA-1273 and were excluded from immunogenicity analyses. Anti-RBD antibodies level and neutralising titres (NT50) against G614, Beta, Mu, Delta and Omicron variants were analyEClinicalMedicine101542https://www.ebi.ac.uk/biostudies/studies/S-EPMC9249303biostudies-literatureImmune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.PMC9249303Perez-Olmeda MImaz-Ayo NPerez-Ingidua CVargas-Castrillon EArrizabalaga JArana-Arri EAlcami JRescueVac study GroupDiez-Fuertes FGarcia-Perez JCastillo de la Osa MPortoles Ade la Torre-Tarazona HEMariano Lazaro ARiano Fernandez IAstasio Gonzalez OHernandez Gutierrez LMeijide SBermejo MVergara IAscaso-Del-Rio AfalseImmune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.<h4>Background</h4>There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens.<h4>Methods</h4>This multicentre, prospective controlled cohort study included subjects who received a COVID-19 experimental vaccine (CVnCoV)(test group, TG) - and unvaccinated subjects (control group, CG), selected among individuals to be vaccinated according to the Spanish vaccination program. All study subjects received BNT162b2 as a standard national vaccination schedule, except 8 (from CG) who received mRNA-1273 and were excluded from immunogenicity analyses. Anti-RBD antibodies level and neutralising titres (NT50) against G614, Beta, Mu, Delta and Omicron variants were analy2022-01-01T00:00:00Z2022 Sep2025-04-26T21:07:35.157Z2022-07-23T08:39:36.107ZS-EPMC92493033579539810.1016/j.eclinm.2022.101542